Skip to content
OpenCapital
Get started

Unicycive Therapeutics, Inc. UNCY Q1 2026 earnings

Reported May 12, 2026 · Before market open

EPS-$0.54Miss by $0.08
Revenue estimate$11.1M
EPS estimate-$0.46

Next report

Aug 13, 2026 (In 2 weeks)
Revenue estimate$22.2M
EPS estimate-$0.47

Versus estimates

Diluted EPS

Q1 2026-$0.54Miss by $0.08
Q4 2025-$0.32Beat by $0.19Q3 2025-$0.39Beat by $0.20Q2 2025-$0.52Beat by $0.18Q1 2025-$0.26Miss by $0.13Q4 2024-$0.16Miss by $0.03

Ask the moment Unicycive Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Unicycive Therapeutics, Inc. report Q1 2026 earnings?
Unicycive Therapeutics, Inc. (UNCY) reported Q1 2026 earnings on May 12, 2026 before market open.
What were Unicycive Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Unicycive Therapeutics, Inc. reported eps of $-0.54 for Q1 2026.
Did Unicycive Therapeutics, Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.46 by $0.08.
How did Unicycive Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 107.7% from $-0.26.
Where can I find Unicycive Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001213900-26-054736) and the 10-Q periodic report (0001213900-26-054708) directly on SEC EDGAR. The filing index links above go to sec.gov.